Genetic selection for dissociative inhibitors of designated protein-protein interactions

Nature Biotechnology

Volumn 18, Issue 8, 2000, Pages 847-851

  Park, Sang Hyun ^a,b   Raines, Ronald T ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Chemical genetics; Drug discovery; Lambda repressor; Peptide library

Indexed keywords

PEPTIDE; PROTEINASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CELL CYCLE; DIMERIZATION; DISSOCIATION; GENETIC SELECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; VIRUS ASSEMBLY; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; BASE SEQUENCE; COMBINATORIAL CHEMISTRY TECHNIQUES; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV PROTEASE; HIV PROTEASE INHIBITORS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING;

EID: 0033896165     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/78451     Document Type: Article

References (57)

1. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface
2. Substrate phage: Selection of protease substrates by monovalent phage display
3. A novel genetic system to detect protein-protein interactions
4. The two-hybrid system: A method to identify and clone genes for proteins that interact with a protein of interest
5. 'Mutagenesis' by peptide aptamers identifies genetic network members and pathway connections
6. Genetic selection of peptide inhibitors of biological pathways
7. Inhibiting the assembly of protein-protein interfaces
8. Active human immunodeficiency virus protease is required for viral infectivity
9. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity
10. HIV-protease inhibitors
11. Inhibitors of HIV-1 protease: A major success of structure-assisted drug design
12. Approaches to the design of effective HIV-1 protease inhibitors
13. Resistance to HIV protease inhibitors: A comparison of enzyme inhibition and antiviral potency
14. HIV-1 reproduction is inhibited by peptides derived from the N- and C-termini of HIV-1 protease
15. Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide
16. Synthetic 'interface' peptides alter dimeric assembly of the HIV 1 and 2 proteases
17. A systematic evaluation of the inhibition of HIV-1 protease by its C-terminal and N-terminal peptides
18. The inhibition of HIV-1 protease by interface peptides
19. Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation
20. The inhibition of human immunodeficiency virus proteases by 'interface peptides'
21. Targeting the dimerization interface of HIV-1 protease: Inhibition with cross-linked interfacial peptides
22. Inhibition of HIV-1 protease by a subunit of didemnaketal A
23. Restricting the flexibility of crosslinked, interfacial peptide inhibitors of HIV-1 protease
24. Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization
25. Lipopeptides as dimerization inhibitors of HIV-1 protease
26. Conserved folding a retroviral proteases: Crystal structure of a synthetic HIV-1 protease
27. The lambda repressor contains two domains
28. Sequence requirements for coiled-coils: Analysis with lambda repressor-GCN4 leucine zipper fusions
29. Modulation of the dimerization of a transcriptional antiterminator protein by phosphorylation
30. Identification of a cDNA for SSRP1, and HMG-box protein, by interaction with the c-Myc oncoprotein in a novel bacterial expression screen
31. Repressor fusions as a tool to study protein-protein interactions
32. Interaction between cAMP-dependent protein kinase catalytic subunit and peptide inhibitors analyzed with lambda repressor fusions
33. Buried asparagines determine the dimerization specificities of leucine zipper mutants
34. Oligomerization properties of GCN4 leucine zipper e and g position mutants
35. Genetic selection of short peptides that support protein oligomerization in vivo
36. Selection and application of peptide-binding peptides
37. Dissociation and association of the HIV-1 protease dimer sub-units: Equilibria and rates
38. Peptide libraries: Criteria and trends
39. Expression of thioredoxin random peptide libraries on the Escherichia coli cell surface as functional fusions to flagellin: A system designed for exploring protein-protein interactions
40. Use of protein unfolding studies to determine the conformational and dimeric stabilities of HIV-1 and SIV proteases
41. The structural stability of the HIV-1 protease
42. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
43. Resistance to HIV protease inhibitors
44. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
45. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
46. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease
47. Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy
48. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development
49. Mutations in retroviral genes associated with drug resistance
50. Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions
51. Design of synthetic gene libraries encoding randora sequence proteins with desired ensemble characteristics
52. Peptides on phage: A vast library of peptides for identifying ligands
53. Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S
54. Multiple sequence alignment with hierarchical clustering
55. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer
56. A transient precursor of the HIV-1 protease. Isolation, characterization, and kinetics of maturation